Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zambon and its partner Newron Pharmaceuticals announced the availability of Xadago (safinamide) in the UK.
Subscribe to our email newsletter
Andrew Lees, MD FRCP, FMedSci, Professor of Neurology, (The National Hospital for Neurology and Neurosurgery, Queen Square and Emeritus Director, Reta Lila, Weston Institute of Neurological Studies, University College London, Institute of Neurology) said: "After 10 years with no new drugs for Parkinson’s disease I welcome the addition of another effective treatment option for patients".
Maurizio Castorina, CEO of Zambon S.p.A. said: "We are committed to developing innovative therapies for patients suffering from PD and other central nervous system diseases. Xadago offers PD patients a novel therapeutic option in the treatment of this progressive disease".
The U.K is the latest country launching Xadago, which is also available in seven other countries: Germany, Switzerland, Spain, Italy, Belgium, Denmark, and Sweden.
‘This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.’
About Xadago (safinamide)
Safinamide is a new chemical entity with a unique mode of action including selective and reversible MAO-B-inhibition and blocking of voltage dependent sodium channels which leads to modulation of abnormal glutamate release. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, with data supporting this effect over 2 years.
Results from 6 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia.
Safinamide is a once-daily dose and has no diet restrictions. Zambon has the rights to develop and commercialize Xadago® globally, excluding Japan and other key territories where Meiji Seika has the rights to develop and commercialize the compound. The rights to develop and commercialize Xadago in the USA have been granted to US WorldMeds, by Zambon.